India, Aug. 5 -- XtalPi Holdings said, in late June 2025, Shenzhen XtalPi Technology, an indirect subsidiary of the company, and DoveTree Medicines and its affiliates entered into a definitive agreement, under which the Group will use its end-to-end AI drug discovery platform through integrated AI + robotics technology to discover and develop small molecule and antibody drug candidates for multiple targets selected by DoveTree. The Group has received an initial payment of $51 million under the Definitive Agreement.
The Group is entitled to receive a further payment of $49 million, and is eligible to receive potential regulatory and commercial milestone payments, as well as potential royalties.
For More Such Health News, visit rttnews.com....